Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials
DOI:
https://doi.org/10.2340/actadv.v106.adv-2025-0160Keywords:
lebrikizumab, atopic dermatitis, moderate-to-severe, Eczema Area and Severity Index, clinical trialAbstract
The ADvocate trials (NCT04146363, NCT04178967) investigated adults/adolescents with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab (LEB) monotherapy, using percent improvement in the Eczema Area and Severity Index (EASI). In clinical trials, percent EASI improvement is used to compare study arms and measure treatment effect size/impact. In clinical practice, however, absolute EASI scores are used (especially in Europe), as they measure an individual’s disease state regardless of baseline severity. This post-hoc analysis assessed absolute EASI response – EASI≤7, ≤5, ≤3, and ≤1 – from the ADvocate trials to understand LEB efficacy in adults/adolescents with moderate-to-severe AD. Week-16 data from patients receiving LEB 250 mg Q2W (n=564) were compared with placebo (n=287). Across baseline moderate/severe/very severe EASI and baseline Investigator’s Global Assessment (IGA) 3/4, significantly higher percentages of patients receiving LEB than those receiving placebo achieved each absolute EASI response. Week--16 LEB EASI 75 responders (n=284) and per-protocol LEB non-responders (n=215) were assessed through week 52. Absolute EASI scores were generally low and stable among responders and reduced among non-responders. Overall, LEB was associated with high rates of durable absolute EASI response, even in cases of high baseline severity or suboptimal week-16 outcomes. Results reflect clinically meaningful improvements that could help guide clinical practice.
Downloads
References
Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol 2018; 36: 595–605. DOI: https://doi.org/10.1016/j.clindermatol.2018.05.007
Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387: 1109–1122. DOI: https://doi.org/10.1016/S0140-6736(15)00149-X
Bylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol 2020; 100: adv00160. DOI: https://doi.org/10.2340/00015555-3510
Drucker AM, Lam M, Elsawi R, Prieto-Merino D, Malek R, Ellis AG, et al. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol 2024; 190: 184–190. DOI: https://doi.org/10.1093/bjd/ljad393
Silverberg JI, Boguniewicz M, Hanifin J, Papp KA, Zhang H, Rossi AB, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis is efficacious regardless of age of disease onset: a post hoc analysis of two phase 3 clinical trials. Dermatol Ther (Heidelb) 2022; 12: 2731–2746. DOI: https://doi.org/10.1007/s13555-022-00822-x
Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol 2021; 35: 1797–1810. DOI: https://doi.org/10.1111/jdv.17351
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis. National Library of Medicine; 2022.
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis. National Library of Medicine; 2023.
Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol 2023; 188: 740–748. DOI: https://doi.org/10.1093/bjd/ljad022
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med 2023; 388: 1080–1091. DOI: https://doi.org/10.1056/NEJMoa2206714
Simpson E, Fernández-Peñas P, de Bruin-Weller M, Lio PA, Chu CY, Ezzedine K, et al. Improvement across dimensions of disease with lebrikizumab use in atopic dermatitis: two phase 3, randomized, double-blind, placebo-controlled monotherapy trials (ADvocate1 and ADvocate2). Adv Ther 2025; 42: 132–143. DOI: https://doi.org/10.1007/s12325-024-02974-y
Guttman-Yassky E, Rosmarin D, de Bruin-Weller M, Weidinger S, Bieber T, Hong HCH, et al. The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials. J Am Acad Dermatol 2025; 92: 1024–1031. DOI: https://doi.org/10.1016/j.jaad.2024.12.026
Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The Eczema area and severity index-A practical guide. Dermatitis 2022; 33: 187–192. DOI: https://doi.org/10.1097/DER.0000000000000895
Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema area and severity index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol 2015; 172: 1353–1357. DOI: https://doi.org/10.1111/bjd.13662
Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, et al. Combining treat‐to‐target principles and shared decision‐making: International expert consensus‐based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. Acad Dermatol Venereol 2024; 38: 2139–2148. DOI: https://doi.org/10.1111/jdv.20229
Schram ME, Spuls PI, Leeflang MMG, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99–106. DOI: https://doi.org/10.1111/j.1398-9995.2011.02719.x
Yeung J, Gooderham MJ, Hong HCH, Lynde C, Prajapati VH, Lansang P, et al. Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: a Canadian perspective. J Am Acad Dermatol 2023; 89: 372–375. DOI: https://doi.org/10.1016/j.jaad.2023.01.053
Puig L, Dossenbach M, Berggren L, Ljungberg A, Zachariae C. Absolute and relative psoriasis area and severity indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis: an integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes. Acta Derm Venereol 2019; 99: 971–977. DOI: https://doi.org/10.2340/00015555-3245
Thyssen JP, Bieber T, Kleyn CE, Nosbaum A, Grond S, Petto H, et al. Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis. J Dermatolog Treat 2023; 34: 2216322. DOI: https://doi.org/10.1080/09546634.2023.2216322
Silverberg JI, Lei D, Yousaf M, Janmohamed SR, Vakharia PP, Chopra R, et al. What are the best endpoints for Eczema area and severity index and scoring atopic dermatitis in clinical practice? A prospective observational study*. Br J Dermatol 2021; 184: 888–895. DOI: https://doi.org/10.1111/bjd.19457
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin). National Library of Medicine; 2025.
Guttman-Yassky E, Weidinger S, Simpson EL, Gooderham M, Irvine AD, Spelman L, et al. Two-year efficacy and safety of lebrikizumab in patients with moderate-to-severe atopic dermatitis: a long-term extension (ADjoin). Dermatol Ther (Heidelb) 2025; 15: 2217–2232. DOI: https://doi.org/10.1007/s13555-025-01452-9
Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 2014; 70: 338–351. DOI: https://doi.org/10.1016/j.jaad.2013.10.010
Downloads
Additional Files
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
